Related Experiment Videos
AngioJet experience from the multi-center STENT Registry
Charles A Simonton1, Bruce R Brodie, Hadley Wilson
1Sanger Clinic, Carolinas Heart Institute, Charlotte, North Carolina 28203, USA. pcichuck@att.net
The Journal of Invasive Cardiology
|August 3, 2006
Summary
AngioJet rheolytic thrombectomy was used in high-risk patients with thrombus, showing a numerically lower mortality rate without safety concerns. This study explored its utilization and outcomes in myocardial infarction patients.
Area of Science:
- Cardiovascular Interventions
- Interventional Cardiology
- Medical Device Technology
Background:
- The Strategic Transcatheter Evaluation of New Therapies (STENT) registry collected data from May 2003 to December 2005.
- Percutaneous coronary intervention (PCI) is a common procedure for managing coronary artery disease.
Purpose of the Study:
- To investigate the use and clinical outcomes of AngioJet Rheolytic thrombectomy.
- To evaluate the safety and efficacy of AngioJet thrombectomy in high-risk patients.
Main Methods:
- Prospective data collection from a multi-center registry.
- Informed consent obtained from 84% of patients undergoing PCI.
- 9-month clinical follow-up achieved in 94% of eligible patients.
Main Results:
- AngioJet was used in 3-4% of all PCI procedures, and in 10-14% of cases with significant thrombus or acute myocardial infarction.
- Patients treated with AngioJet had a similar 9-month mortality rate (5.0%) compared to those without thrombectomy (6.5%) despite higher baseline risk.
- The AngioJet group had a higher prevalence of cardiogenic shock and larger thrombus burden.
Conclusions:
- AngioJet thrombectomy is utilized in selected high-risk patients with significant thrombus.
- The procedure demonstrated a non-significant, numerically lower mortality rate.
- No safety issues were identified, suggesting AngioJet is a safe option for selected patients.